Curtis Raskin, MD
Dermatology · Pleasant Hill, CANPI 1154358034
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,924 of the $2,249 with a category attached, or 85.5%. 16 manufacturers reported payments, led by AbbVie at 31.0% of the total. Reporting peaked in 2024 at $683 and has fallen 54.1% since, to $314 in 2025.
Across 98 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$698
- Johnson & Johnson$530
- Pfizer$240
- Novartis$148
- LEO Pharma Inc.$135
- Arcutis Biotherapeutics, Inc.$112
- plus $386 from 10 others
What the payments were for
- Food & beverage$1,92486%
- Education$32514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $698 |
| Johnson & Johnson | 16 | $530 |
| Pfizer | 6 | $240 |
| Novartis | 5 | $148 |
| LEO Pharma Inc. | 3 | $135 |
| Arcutis Biotherapeutics, Inc. | 6 | $112 |
| Dermavant Sciences, Inc. | 5 | $97 |
| Organon | 2 | $52 |
| Amgen | 3 | $47 |
| Boehringer Ingelheim | 1 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Incyte Corporation | 1 | $28 |
| Lilly USA, LLC | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Almirall LLC | 1 | $22 |
| Sanofi | 1 | $16 |
How this compares
$2,249 in reported general payments places this provider in the 55th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 37 | $773,148 |
| Dupixent PenDupilumab | 36 | $128,228 |
| Taltz AutoinjectorIxekizumab | 11 | $76,698 |
| Fluorouracil | 149 | $11,574 |
| Ketoconazole | 620 | $10,851 |
| Metronidazole | 138 | $7,688 |
| Clobetasol Propionate | 148 | $3,898 |
| Tacrolimus | 45 | $3,583 |
| Doxycycline Hyclate | 133 | $3,421 |
| ValacyclovirValacyclovir Hcl | 107 | $2,540 |
| Triamcinolone Acetonide | 373 | $2,386 |
| Fluocinonide | 81 | $1,927 |
| Calcipotriene | 17 | $1,894 |
| Selenium Sulfide | 68 | $1,378 |
| Pimecrolimus | 12 | $1,358 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Pleasant Hill
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
- Tina BhutaniSan Francisco$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.